Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

Saruparib, ZYTIGA 500 mg film-coated tablets, Erleada 60 mg film-coated tablets, Saruparib, Xtandi - 40 mg soft capsules, Prednisone Mylan Pharma 5 mg compresse, NUBEQA 300 mg film-coated tablets, Saruparib

Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib

TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets

TD001

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone

TRUQAP 200 mg film-coated tablets, TRUQAP 160 mg film-coated tablets

Testosterone Enanthate 100 MG/ML Injectable Solution

Testosterone cypionate

Tozorakimab

Tozorakimab-placebo, Tozorakimab, SALBUTAMOL

Trastuzumab deruxtecan

Tremelimumab placebo, concentrate for solution for infusion, Tremelimumab

Venclyxto 100 mg film-coated tablets, RITUXIMAB, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, RITUXIMAB, Venclyxto 10 mg film-coated tablets

Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets

Volrustomig

Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

Zibotentan, DAPAGLIFLOZIN, Zibotentan placebo, Dapagliflozin placebo

osimertinib

15O-WATER, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, AZD3427, Dopamin Fresenius 50 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung, Placebo for AZD3427 or AZD3427 diluent

A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus

A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors

A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Frequently asked questions